Drug Trial Radar · NCT02226120
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
Last checked: Nov 19, 2026Latest source record: Feb 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,980
Actual
Start
Oct 16, 2014
Primary completion
Dec 28, 2017
Study completion Dec 28, 2017
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 27, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug. The parent PARADIGM-HF (NCT01035255) trial was terminated early due to compelling efficacy of LCZ696 in patients with heart failure with reduced ejection fraction (HFrEF) after the final pre-specified interim analysis in March 2014.
Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
Interventions
LCZ696Drug
Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability of LCZ696Time frame: From first dose of study treatment to 30 days after last dose of study treatment, up to 30 months.
Locations
394 sites in 41 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Huntsville, Alabama
Novartis Investigative Site
Muscle Shoals, Alabama
Novartis Investigative Site
Little Rock, Arkansas
Novartis Investigative Site
Oceanside, California
Novartis Investigative Site
Palm Springs, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
Santa Rosa, California
Novartis Investigative Site
Boynton Beach, Florida
Novartis Investigative Site
Des Moines, Iowa
Novartis Investigative Site
Covington, Louisiana
Novartis Investigative Site
Columbia, Maryland
Novartis Investigative Site
Saginaw, Michigan
Novartis Investigative Site
Minneapolis, Minnesota
Novartis Investigative Site
Fremont, Nebraska
Novartis Investigative Site
New York, New York
Novartis Investigative Site
Rosedale, New York
Novartis Investigative Site
Raleigh, North Carolina
Novartis Investigative Site
Marion, Ohio
Novartis Investigative Site
Rapid City, South Dakota
Novartis Investigative Site
Dallas, Texas
Novartis Investigative Site
Dallas, Texas
Novartis Investigative Site
Livingston, Texas
Novartis Investigative Site
Spokane, Washington
Novartis Investigative Site
Waukesha, Wisconsin
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Corrientes, Argentina
Novartis Investigative Site
Formosa, Argentina
Novartis Investigative Site
Formosa, Argentina
Novartis Investigative Site
Mendoza, Argentina
Novartis Investigative Site
San Luis, Argentina
Novartis Investigative Site
Santa Fe, Argentina
Novartis Investigative Site
Santa Fe, Argentina
Novartis Investigative Site
Santiago del Estero, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Ciudad Autonoma de Bs As, Buenos Aires, Argentina
Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina
Novartis Investigative Site
Quilmes, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires F.D., Argentina
Showing 40 of 394 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.